<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40397909</article-id><article-id pub-id-type="pmc">PMC12094769</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0323965</article-id><article-id pub-id-type="publisher-id">PONE-D-24-44183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Carcinoma</subject><subj-group><subject>Hepatocellular Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Gastrointestinal Tumors</subject><subj-group><subject>Hepatocellular Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Liver Diseases</subject><subj-group><subject>Hepatocellular Carcinoma</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Processes</subject><subj-group><subject>Cell Death</subject><subj-group><subject>Apoptosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Genitourinary Tract Tumors</subject><subj-group><subject>Prostate Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Prostate Diseases</subject><subj-group><subject>Prostate Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Head and Neck Cancers</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Colorectal Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Genitourinary Cancers</subject><subj-group><subject>Testicular Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Genitourinary Tract Tumors</subject><subj-group><subject>Testicular Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>High <italic toggle="yes">SRD5A3</italic> expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis</article-title><alt-title alt-title-type="running-head">SRD5A3 promotes the development of B-cell non-Hodgkin lymphoma</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Shanshan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="econtrib001" ref-type="author-notes">
<sup>&#x0262f;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jie</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="econtrib001" ref-type="author-notes">
<sup>&#x0262f;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Jiahao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="econtrib001" ref-type="author-notes">
<sup>&#x0262f;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Jianing</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xuan</surname><given-names>Yixuan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jingyu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Jie</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4213-9310</contrib-id><name><surname>Zhang</surname><given-names>Jianfeng</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Emergency, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Hematological Oncology and Pediatric Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Imaging Medicine, Guigang City People&#x02019;s Hospital, Guigang, Guangxi, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of general practice, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>The Center for Clinical Medical Research, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Bertolini</surname><given-names>Francesco</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>European Institute of Oncology, ITALY</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="other" id="econtrib001"><p>&#x0262f; These authors have contributed equally to this work and share first authorship</p></fn><corresp id="cor001">* E-mail: <email>shenggj1992@163.com</email> (JY), <email>zhangjianfeng@gxmu.edu.cn</email> (JZ)</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0323965</elocation-id><history><date date-type="received"><day>10</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Wei et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wei et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0323965.pdf">
</self-uri><abstract><sec id="sec001"><title>Background</title><p>Steroid 5&#x003b1;-reductase 3 (<italic toggle="yes">SRD5A3</italic>) is an important molecule involved in glycosylation and steroid hormone formation and is highly expressed in most tumors. However, The role of <italic toggle="yes">SRD5A3</italic> in B-cell non-Hodgkin lymphoma (B-NHL) and its mechanism are unknown.</p></sec><sec id="sec002"><title>Methods</title><p>We used a multi-omics database to explore the expression and prognostic significance of <italic toggle="yes">SRD5A3</italic> in various tumors, including B-NHL. We established <italic toggle="yes">SRD5A3</italic> high- and low-expression B-NHL cell lines to test the effects of <italic toggle="yes">SRD5A3</italic> on cell proliferation and apoptosis in vitro, and to analyze the signaling pathways associated with the effects of <italic toggle="yes">SRD5A3</italic> on B-NHL.</p></sec><sec id="sec003"><title>Results</title><p>We found that <italic toggle="yes">SRD5A3</italic> was highly expressed in most tumors, including B-NHL, and was more highly expressed in patients age &#x02265;60 years, high levels of LDH, stage III-IV, non-GCB subtype, and extra-nodal invasion. Survival analysis showed that high <italic toggle="yes">SRD5A3</italic> expression predicted poorer overall survival (OS). Further experiments showed that <italic toggle="yes">SRD5A3</italic> high expression promoted B-NHL growth and attenuates apoptosis, conversely, <italic toggle="yes">SRD5A3</italic> low expression inhibited B-NHL growth and promoted apoptosis. Western blot assay showed <italic toggle="yes">SRD5A3</italic> promotes B-NHL cells growth by regulating the PI3K-AKT signaling pathway.</p></sec><sec id="sec004"><title>Conclusions</title><p>Our findings suggest that <italic toggle="yes">SRD5A3</italic> exerts its oncogenic effects by regulating the PI3K-AKT pathway, may serve as a potential biomarker and therapeutic target for B-NHL, providing information for clinical decision-making.</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="13"/><table-count count="0"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its <xref rid="sec026" ref-type="sec">Supporting Information</xref> files</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its <xref rid="sec026" ref-type="sec">Supporting Information</xref> files</p></notes></front><body><sec sec-type="intro" id="sec005"><title>1. Introduction</title><p>Non-Hodgkin&#x02019;s lymphoma (NHL) is a heterogeneous disease caused by malignant transformation of lymphocytes, with 60&#x02013;80% originating from B cells. Aggressive B-cell non-Hodgkin lymphoma (B-NHL) is the most common subtype of NHL, mainly comprising diffuse large B-cell lymphoma (DLBCL), Burkitt&#x02019;s lymphoma (BL), and Mantle-cell lymphoma (MCL) [<xref rid="pone.0323965.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0323965.ref003" ref-type="bibr">3</xref>], and is a clinically and genetically heterogeneous disease. Current treatments for B-NHL include rituximab&#x02009;+&#x02009;cyclophosphamide&#x02009;+&#x02009;vincristine&#x02009;+&#x02009;doxorubicin&#x02009;+&#x02009;prednisone (R-CHOP)-targeted chemotherapy, autologous stem cell transplantation (ASCT) and chimeric antigen receptor T cell (CAR-T) therapy. Despite significant advances in the treatment and management of B-NHL, approximately 30%-50% of B-NHL patients exhibit disease progression or relapse, the mechanisms of which are not fully understood [<xref rid="pone.0323965.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0323965.ref005" ref-type="bibr">5</xref>]. One of the main reasons for this is resistance to chemotherapeutic agents. Resistance may be related to overexpression of specific proteins on the tumor cell membrane or within the tumor cells caused by genetic mutations [<xref rid="pone.0323965.ref006" ref-type="bibr">6</xref>]. Gene-targeted therapies have emerged as a potential strategy to overcome resistance to cancer chemotherapeutic agents.</p><p>According to data released by the Global Cancer Center, the incidence of lymphoma in China is about 6.68/100,000 people, with approximately 100,000 new cases each year, and the incidence of B-NHL in China is on the rise [<xref rid="pone.0323965.ref007" ref-type="bibr">7</xref>]. Risk stratification included the International Prognostic Index (IPI), age-adjusted International Prognostic Index (aaIPI), and National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) [<xref rid="pone.0323965.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0323965.ref009" ref-type="bibr">9</xref>]. Differences in gene expression profiles (GEPs) and gene alterations can lead to significant differences in treatment responses and clinical courses [<xref rid="pone.0323965.ref010" ref-type="bibr">10</xref>]. With the advent and development of next-generation sequencing technologies, many studies have shown that genetic alterations, such as EZH2, MYD88, CD79B, and BCL2, are associated with the development of B-NHL [<xref rid="pone.0323965.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0323965.ref015" ref-type="bibr">15</xref>]. The identification of new biomarkers may help refine risk stratification, inform treatment decisions, and predict treatment response and clinical outcomes.</p><p>Steroid 5 alpha-reductase 3(<italic toggle="yes">SRD5A3</italic>) is a protein-coding gene belonging to the steroid 5-alpha reductase family and is important for glycosylation metabolism and steroid hormone formation [<xref rid="pone.0323965.ref016" ref-type="bibr">16</xref>]. Steroid hormones are essential for mammalian stress response, immune system regulation, and reproduction. Glycosylation is an important post-translational modification that can alter the conformation and stability of proteins [<xref rid="pone.0323965.ref017" ref-type="bibr">17</xref>]. Aberrant glycosylation is closely associated with several pathological processes, including tumorigenesis and inflammatory responses [<xref rid="pone.0323965.ref018" ref-type="bibr">18</xref>]. Many studies have reported high expression of <italic toggle="yes">SRD5A3</italic> in liver, breast, endometrial, and prostate cancers, and its high expression is associated with poor prognosis [<xref rid="pone.0323965.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0323965.ref021" ref-type="bibr">21</xref>], which is a cancer-promoting effect and is involved in the proliferation of cancer cells [<xref rid="pone.0323965.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0323965.ref022" ref-type="bibr">22</xref>]. However, the clinical significance and mechanism of action of <italic toggle="yes">SRD5A3</italic> in B-NHL remain unclear.</p><p>In this study, in order to evaluate the prognostic factors of B-NHL, we analyzed the clinical data of B-NHL patients using a multi-omics database and analyzed the relationship between <italic toggle="yes">SRD5A3</italic> expression and clinicopathological characteristics and overall survival (OS) of B-NHL patients. We also investigated the role of <italic toggle="yes">SRD5A3</italic> in the development of B-NHL by in vitro functional assays and explored the potential mechanisms by which <italic toggle="yes">SRD5A3</italic> regulates cell proliferation and apoptosis.</p></sec><sec sec-type="materials|methods" id="sec006"><title>2. Materials and methods</title><sec id="sec007"><title>2.1 Bioinformatics analysis</title><p>We used B-NHL datasets from several different databases: (1)The pan-cancer dataset was downloaded from the UCSC database (<ext-link xlink:href="https://xenabrowser.net/" ext-link-type="uri">https://xenabrowser.net/</ext-link>), and the expression data of <italic toggle="yes">SRD5A3</italic> gene were extracted, including 12,713 cancer samples and 10,505 normal samples; (2) <italic toggle="yes">SRD5A3</italic> transcript expression and survival information of 47 B-NHL patients from The Cancer Genome Atlas (TCGA; <ext-link xlink:href="https://cancergenome.nih.gov/" ext-link-type="uri">https://cancergenome.nih.gov/</ext-link>) database; (3) transcriptomic data from 337 normal donors obtained from the Genotype-Tissue Expression Database (GTEx; <ext-link xlink:href="https://gtexportal.org" ext-link-type="uri">https://gtexportal.org</ext-link>); (4) <italic toggle="yes">SRD5A3</italic> transcript expression and survival information of 233 B-NHL patients, 55 B-NHL patients, 33 normal control samples,76 B-NHL patients, and 87 normal control samples from the Gene Expression Omnibus (GEO) database (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link>; accession numbers GSE10846, GSE56315, and GSE83632). The public database data used in our study were publicly available online, and the experiments in this study had no ethical implications, so no additional ethical and moral statements were required.</p></sec><sec id="sec008"><title>2.2 Plasmid</title><p>For the shRNA plasmid, the lentiviral vector pHBLV-U6-MCS-CMV-ZsGreen-PGK-PURO was employed. A negative control (NC) virus, HBLV-ZsGreen-PURO NC, was designed with the following primers: sense strand: 5&#x02032;-GATCCGTTCTCCGAACGTGTCACGTAATTCAAGAGATTACGTGACACGTTCGGAGAATTTTTTC-3&#x02032;, antisense strand: 5&#x02032;-AATTGAAAAAATTCTCCGAACGTGTCACGTAATCTCTTGAATTACGTGACACGTTCGGAGAACG-3&#x02032;. The shRNA sequence targeting <italic toggle="yes">SRD5A3</italic> (HBLV-h-<italic toggle="yes">SRD5A3</italic> shRNA1-ZsGreen-PURO) was synthesized and cloned into the vector using the following primers: sense strand: 5&#x02032;-GATCCGTGCATTCTTAGTGCTAGTATTctcgagAATACTAGCACTAAGAATGCATTTTTTG-3&#x02032;, antisense strand: 5&#x02032;-AATTCAAAAAATGCATTCTTAGTGCTAGTATTctcgagAATACTAGCACTAAGAATGCACG-3&#x02032;. For the overexpression plasmid, the lentiviral vector pHBLV-CMV-MCS-EF1-ZsGreen-T2A-puro was utilized. The empty vector (HBLV-ZsGreen-PURO) served as the control. The <italic toggle="yes">SRD5A3</italic> overexpression construct (HBLV-h-<italic toggle="yes">SRD5A3</italic>-Null-ZsGreen-PURO) was generated using the following primers: sense primer: 5&#x02032;-ctagaggatctatttccggtgaattcgccaccATGGCTCCCTGGGCGGAGGC-3&#x02032;, antisense primer: 5&#x02032;-agatccttactagtatcgatggatccTTAAAACAAAAATGGTAGGAAAG-3&#x02032;.</p></sec><sec id="sec009"><title>2.3 Cell culture and transfection</title><p>The human B-cell lymphoma cell line SU-DHL-4 was purchased from Procell (Wuhan, China) and Raji was purchased from the Chinese Academy of Sciences (Shanghai, China). Both cell lines were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% antibiotics. To construct cell lines overexpressing or knocking down <italic toggle="yes">SRD5A3</italic>, SU-DHL-4 and Raji cells were infected with lentiviruses containing the indicated plasmids (HBLV-ZsGreen-PURO, HBLV-h-<italic toggle="yes">SRD5A3</italic>-Null-ZsGreen-PURO, HBLV-ZsGreen-PURO NC, and HBLV-h-<italic toggle="yes">SRD5A3</italic>-shRNA1-ZsGreen-PURO), respectively. Raji cells were knocked down <italic toggle="yes">SRD5A3</italic> to obtain sh-<italic toggle="yes">SRD5A3</italic> cells, and SU-DHL-4 cells were overexpressed <italic toggle="yes">SRD5A3</italic> to obtain oe-<italic toggle="yes">SRD5A3</italic> cells, their controls were sh-NC cells and oe-NC cells, respectively.</p></sec><sec id="sec010"><title>2.4 Quantitative Real-time PCR</title><p>TRIzol reagent (Invitrogen) was used to extract total RNA, which was reverse transcribed into cDNA. Real-time fluorescence quantitative PCR was performed using one-step Hieff qPCR SYBR Green Master Mix (No Rox) (Yeasen, China) according to the&#x000a0;manufacturer's&#x000a0;instructions. The relative levels of <italic toggle="yes">SRD5A3</italic> cDNA were calculated as 2-&#x00394;&#x00394;Ct and normalized to the human GAPDH gene. The upstream primer for <italic toggle="yes">SRD5A3</italic> was 5&#x02019;-TGGCTGCACAGCTTACGAAG- 3&#x02019; and the downstream primer was 5-TCAGCACAGTTAGGCCAACAA-3&#x02019;; for GAPDH, the upstream primer was 5&#x02019;-GCACCGTCAAGGCTGAGAAC-3&#x02019; and the downstream primer was 5&#x02019;- TGGTGAAGACGCCAGTGGA- 3&#x02019;.</p></sec><sec id="sec011"><title>2.5 Cell proliferation assay</title><p>The CCK-8 assay was used to determine cell proliferation. <italic toggle="yes">SRD5A3</italic> overexpression cells oe-<italic toggle="yes">SRD5A3</italic>, control cells oe-NC, <italic toggle="yes">SRD5A3</italic> knockdown cells sh-<italic toggle="yes">SRD5A3</italic>, and control sh-NC cells were inoculated in 96-well plates at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL, and three replicate wells were prepared for each group of cells. At 0h, 24h, 48h and 72h, 10 &#x003bc;L of CCK-8 working solution was added and incubated for 3h away from light, and he absorbance was measured at 450&#x02009;nm (OD450). Growth curves for each group of cells were plotted.</p></sec><sec id="sec012"><title>2.6 Apoptosis assay</title><p>The apoptosis rate was determined using an Annexin V-APC/7-AAD Apoptosis Kit (MULTISCIENCES, China). The oe-<italic toggle="yes">SRD5A3</italic> and oe-NC cells and sh-<italic toggle="yes">SRD5A3</italic> and sh-NC cells with good growth status and more than 80% cell fusion were taken and stained with membrane-bound proteins V-APC and 7-AAD according to the instructions, so that the liquid was mixed well, and then incubated for 15 minutes at room temperature away from light, and apoptosis was detected by using flow cytometer in 1&#x02009;h. The cells were then incubated for 15&#x02009;min at room temperature in the dark, and apoptosis was detected using flow cytometry. The experiments were performed in 3 biological replicates.</p></sec><sec id="sec013"><title>2.7 Western blot</title><p>Cells with a growth density of 80% or higher were collected, washed twice with pre-cooled PBS, added to an appropriate amount of cell lysate (RIPA Total Protein Lysate: PMSF&#x02009;=&#x02009;100:1, prepared 5&#x02009;min before use), mixed well, and lysed on ice for 30&#x02009;min. The resulting cell lysates were centrifuged at 12,000&#x02009;rpm for 15 minutes at 4&#x000b0;C. The supernatant was aspirated into a new pre-cooled 1.5&#x02009;ml EP tube, and the protein concentration was detected and recorded on a UV spectrophotometer. Proteins were separated by SDS-PAGE and electrotransferred onto polyvinylidene fluoride (PVDF) membranes. After 1&#x02009;h of closure at room temperature, the membrane was incubated with the primary antibody at 4&#x000b0;C overnight, followed by incubation with the secondary antibody for 1&#x02013;2 hours at room temperature. Blots were visualized using the Odyssey gel&#x000a0;image&#x000a0;system and analyzed using the ImageJ software. Primary antibodies against GAPDH, <italic toggle="yes">SRD5A3</italic>, BCL-2, PCNA, N-cadherin, Vimentin, PI3K, p-PI3K, AKT and p-AKT were purchased from Proteintech (Wuhan, China).</p></sec><sec id="sec014"><title>2.8 Statistical analysis</title><p>R 4.3.1, SPSS 26.0, and GraphPad Prism 9 software were used to analyze the data, and graphs, respectively. Data are expressed as the mean&#x02009;&#x000b1;&#x02009;standard deviation (X&#x02009;&#x000b1;&#x02009;SD). Comparison of the means of the two samples was performed using the t-test; univariate survival analysis was performed using the Kaplan-Meier method and tested by the log-rank method, and multifactorial survival analysis was analyzed by Cox regression. Statistical significance was set at p&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="results" id="sec015"><title>3. Results</title><sec id="sec016"><title>3.1 SRD5A3 is highly expressed in most tumors including B-NHL and suggests a poor prognosis</title><p>The workflow diagram is shown in <xref rid="pone.0323965.g001" ref-type="fig">Fig 1</xref>. To determine the expression of <italic toggle="yes">SRD5A3</italic> in pan-cancer and its relationship with prognosis, we collected <italic toggle="yes">SRD5A3</italic> transcriptional expression and survival information of various tumors and normal control samples from TCGA and GTEx databases and analyzed the expression of <italic toggle="yes">SRD5A3</italic> in various tumor and normal control tissues using Sangerbox software (<xref rid="pone.0323965.g002" ref-type="fig">Fig 2A</xref>). We used The Human Protein Atlas (HPA) website to analyze the immunohistochemistry of <italic toggle="yes">SRD5A3</italic> in tumor and normal tissues and found that the expression of <italic toggle="yes">SRD5A3</italic> was higher in lymphoma, pancreatic cancer, and testicular cancer than in normal tissues (<xref rid="pone.0323965.g002" ref-type="fig">Fig 2B</xref>). We used the R package to perform pan-cancer survival analysis of <italic toggle="yes">SRD5A3</italic> (<xref rid="pone.0323965.g003" ref-type="fig">Fig 3</xref>). The results showed that <italic toggle="yes">SRD5A3</italic> was highly expressed in most tumors compared to normal tissues, and patients with <italic toggle="yes">SRD5A3</italic> high expression had shorter overall survival.</p><fig position="float" id="pone.0323965.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g001</object-id><label>Fig 1</label><caption><title>Workflow chart.</title></caption><graphic xlink:href="pone.0323965.g001" position="float"/></fig><fig position="float" id="pone.0323965.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g002</object-id><label>Fig 2</label><caption><title>Expression of <italic toggle="yes">SRD5A3</italic> in pan-cancer.</title><p><bold>A.</bold> Expression of <italic toggle="yes">SRD5A3</italic> in pan-cancer and normal tissues. B. Immunohistochemistry of <italic toggle="yes">SRD5A3</italic> in B-NHL, PAAD, TGCT and normal tissues. The significance is marked as p&#x02009;&#x0003c;&#x02009;0.05 *; p&#x02009;&#x0003c;&#x02009;0.01 **; p&#x02009;&#x0003c;&#x02009;0.001 ***; p&#x02009;&#x0003c;&#x02009;0.0001 ****. Abbreviation: GBM, Glioblastoma; HNSC, GBMLGG, Glioma; LGG, Lower Grade Glioma; UCEC, Endometrioid Cancer; BRCA,Breast Cancer; CESC, Cervical Cancer; LUAD, Lung Adenocarcinoma; ESCA, Esophageal carcinoma; STES, Stomach and Esophageal carcinoma; KIRP,Kidney Papillary Cell Carcinoma; KIPAN, Pan-kidney cohort (KICH+KIRC+KIRP); COAD, Colon Cancer; COADREAD, Colon adenocarcinoma/Rectum adenocarcinoma Esophageal carcinoma; PRAD, Prostate Cancer; STAD,Stomach Cancer; HNSC, Head and Neck squamous cell carcinoma; KIRC, Kidney renal clear cell carcinoma; LUSC, Lung Squamous Cell Carcinoma; LIHC, Liver hepatocellular carcinoma; WT, Wilms Tumor; SKCM, Melanoma; BLCA, Bladder Urothelial Carcinoma; THCA,Thyroid Cancer; READ, Rectal Cancer; OV, Ovarian Cancer; PAAD, Pancreatic Cancer; TGCT, Testicular Cancer; UCS, Uterine Carcinosarcoma; ALL, Acute Lymphoblastic Leukemia; LAML, Acute Myeloid Leukemia; PCPG,Pheochromocytoma &#x00026; Paraganglioma; ACC, Adrenocortical Cancer; KICH,Kidney Chromophobe; CHOL, Bile Duct Cancer.</p></caption><graphic xlink:href="pone.0323965.g002" position="float"/></fig><fig position="float" id="pone.0323965.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g003</object-id><label>Fig 3</label><caption><title>Survival analysis of <italic toggle="yes">SRD5A3</italic> in pan-cancer.</title><p>P&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g003" position="float"/></fig></sec><sec id="sec017"><title>3.2 SRD5A3 expression is associated with adverse clinicopathologic features in B-NHL</title><p>To understand the expression of <italic toggle="yes">SRD5A3</italic> in B-NHL and normal tissues, we analyzed the expression of <italic toggle="yes">SRD5A3</italic> in 55 B-NHL patients and 33 normal control samples in the GSE56315 dataset, as well as analyzed the expression of <italic toggle="yes">SRD5A3</italic> in 76 B-NHL patients and 87 normal control samples in the GSE83632 dataset. The results showed that the expression of <italic toggle="yes">SRD5A3</italic> was significantly higher in B-NHL tissues than in normal tissues (<xref rid="pone.0323965.g004" ref-type="fig">Fig 4A</xref>-<xref rid="pone.0323965.g004" ref-type="fig">B</xref>). We also analyzed the differential expression of <italic toggle="yes">SRD5A3</italic> in different clinicopathological subgroups of the GSE10846 dataset, the same treatment regimen was used for all of these sample. The results showed that <italic toggle="yes">SRD5A3</italic> expression was higher in patients with &#x02265;60 years old, high LDH levels, stage III-IV, non-GCB subtype, and extranodal invasion (<xref rid="pone.0323965.g004" ref-type="fig">Fig 4C</xref>-<xref rid="pone.0323965.g004" ref-type="fig">G</xref>), whereas there were no significant differences in ECOG score subgroups (<xref rid="pone.0323965.g004" ref-type="fig">Fig 4H</xref>).</p><fig position="float" id="pone.0323965.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g004</object-id><label>Fig 4</label><caption><title>Expression of <italic toggle="yes">SRD5A3</italic> in various clinicopathologic features in B-NHL.</title><p>A. <italic toggle="yes">SRD5A3</italic> expression in B-NHL and normal tissues in the GSE56315 dataset. B. <italic toggle="yes">SRD5A3</italic> expression in B-NHL and normal tissues in the GSE83632 dataset. C. <italic toggle="yes">SRD5A3</italic> expression in different age groups. D. <italic toggle="yes">SRD5A3</italic> expression in different LDH levels. E. <italic toggle="yes">SRD5A3</italic> expression in different clinical stages. F. <italic toggle="yes">SRD5A3</italic> expression in different subtype. G. <italic toggle="yes">SRD5A3</italic> expression in different numbers of Extranodal invasion site. H. <italic toggle="yes">SRD5A3</italic> expression in different ECOG scores. P&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g004" position="float"/></fig></sec><sec id="sec018"><title>3.3 Construction of a prognostic model containing SRD5A3</title><p>To investigate whether <italic toggle="yes">SRD5A3</italic> could serve as a prognostic marker for B-NHL, we analyzed the effects of different clinicopathological features on OS in the GSE10846 dataset using univariate COX regression. the same treatment regimen was used for all of these sample. The results showed that patients in the group with low <italic toggle="yes">SRD5A3</italic> expression, age&#x02009;&#x0003c;&#x02009;60 years, low LDH level, low ECOG score, low clinical stage, GCB subtype, and patients without extranodal invasion had a longer overall survival (<xref rid="pone.0323965.g005" ref-type="fig">Fig 5A</xref>-<xref rid="pone.0323965.g005" ref-type="fig">G</xref>), whereas sex had no significant effect on prognosis (<xref rid="pone.0323965.g005" ref-type="fig">Fig 5H</xref>).</p><fig position="float" id="pone.0323965.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g005</object-id><label>Fig 5</label><caption><title>Univariate COX regression analysis of different clinicopathologic features on OS in B-NHL.</title><p>A. Effect of <italic toggle="yes">SRD5A3</italic> expression on OS. B. Effect of age on OS. C. Effect of LDH on OS. D. Effect of ECOG score on OS. E. Effect of clinical stage on OS. F. Effect of subtype on OS. G. Effect of the number of extranodal invasion sites on OS. H. Effects of gender on OS. P&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g005" position="float"/></fig><p>Next, we performed a correlation analysis between <italic toggle="yes">SRD5A3</italic> and these clinicopathological features, which showed that there were correlations between <italic toggle="yes">SRD5A3</italic> and LDH and stage, whereas the correlations were not significant for age, sex, ECOG score, subtype, and extranodal invasion (<xref rid="pone.0323965.g006" ref-type="fig">Fig 6A</xref>). This shows that there is covariance between <italic toggle="yes">SRD5A3</italic> and LDH and stage. We combined the results of expression analysis, univariate COX regression analysis and correlation analysis, we included <italic toggle="yes">SRD5A3</italic>, age, subtype, and extranodal invasion in multivariate COX regression survival analysis and found that <italic toggle="yes">SRD5A3</italic>, subtype, and extranodal invasion were independent prognostic factors for OS in B-NHL patients, the C-index of nomogram was 0.72<italic toggle="yes">5</italic> (<xref rid="pone.0323965.g006" ref-type="fig">Fig 6B</xref>-<xref rid="pone.0323965.g006" ref-type="fig">C</xref>). These factors were combined to establish a prognostic prediction model for B-NHL, and the ROC curve showed that this prognostic model had a moderate ability to predict the 1-year, 3-years and 5-years survival rates of B-NHL patients (<xref rid="pone.0323965.g006" ref-type="fig">Fig 6D</xref>).</p><fig position="float" id="pone.0323965.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g006</object-id><label>Fig 6</label><caption><title>Multivariate COX regression analyses and construction of prognostic prediction model.</title><p>A. Correlation analysis between <italic toggle="yes">SRD5A3</italic> and different clinicopathologic features. B. Multivariate COX regression analysis of OS. C. Nomogram for prognostic modeling. D. ROC curve of the prediction model. The significance is marked as p&#x02009;&#x0003c;&#x02009;0.05 *; p&#x02009;&#x0003c;&#x02009;0.01 **; p&#x02009;&#x0003c;&#x02009;0.001 ***; p&#x02009;&#x0003c;&#x02009;0.0001 ****; p&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g006" position="float"/></fig></sec><sec id="sec019"><title>3.4 Signaling pathways associated with SRD5A3</title><p>To explore the relevant signaling pathways for <italic toggle="yes">SRD5A3</italic> action, we performed GSEA pathway enrichment analysis on TCGA and GSE56315 datasets. The results showed that the differentially expressed genes were mainly enriched in signaling pathways such as apoptosis, JAK-STAT, PI3K-AKT, and transcription factor dysregulation in cancer (<xref rid="pone.0323965.g007" ref-type="fig">Fig 7A</xref>-<xref rid="pone.0323965.g007" ref-type="fig">B</xref>). These results suggest that <italic toggle="yes">SRD5A3</italic> promotes tumor development through these pathways.</p><fig position="float" id="pone.0323965.g007"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g007</object-id><label>Fig 7</label><caption><title>Gene Set Enrichment Analysis.</title><p>A. Pathway enrichment analysis of the TCGA dataset. B. Pathway enrichment analysis of the GSE56315 dataset. P&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g007" position="float"/></fig></sec><sec id="sec020"><title>3.5 Lentiviral transfection to construct SRD5A3 overexpression and suppressed expression cell lines</title><p>To alter <italic toggle="yes">SRD5A3</italic> expression in vitro, we performed RT-qPCR analysis on several B-NHL cells, knocked down the highest <italic toggle="yes">SRD5A3</italic>-expressed Raji cells, and overexpressed the lowest <italic toggle="yes">SRD5A3</italic>-expressed SU-DHL-4 cells (<xref rid="pone.0323965.g008" ref-type="fig">Fig 8A</xref>). Lentiviral constructs carrying oe-<italic toggle="yes">SRD5A3</italic>, sh-<italic toggle="yes">SRD5A3</italic>, and the corresponding empty vectors were transfected into SU-DHL-4 and Raji cells to overexpress or knockdown <italic toggle="yes">SRD5A3</italic>. Cellular green fluorescent protein (GFR) expression was observed under an inverted fluorescence phase-contrast microscope (<xref rid="pone.0323965.g008" ref-type="fig">Fig 8B</xref>,<xref rid="pone.0323965.g008" ref-type="fig">8E</xref>), and <italic toggle="yes">SRD5A3</italic> cDNA and protein levels were detected by RT-qPCR and western blotting. The results showed that sh-NC and oe-NC did not alter <italic toggle="yes">SRD5A3</italic> expression. The <italic toggle="yes">SRD5A3</italic> cDNA level was significantly decreased in sh-<italic toggle="yes">SRD5A3</italic> and increased in oe-<italic toggle="yes">SRD5A3</italic> (<xref rid="pone.0323965.g008" ref-type="fig">Fig 8C</xref>,<xref rid="pone.0323965.g008" ref-type="fig">8F</xref>); whereas <italic toggle="yes">SRD5A3</italic> protein levels were significantly decreased in sh-<italic toggle="yes">SRD5A3</italic> and increased in oe-<italic toggle="yes">SRD5A3</italic>(<xref rid="pone.0323965.g008" ref-type="fig">Fig 8D</xref>,<xref rid="pone.0323965.g008" ref-type="fig">8G</xref>).</p><fig position="float" id="pone.0323965.g008"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g008</object-id><label>Fig 8</label><caption><title>Construction of cell models with <italic toggle="yes">SRD5A3</italic> suppressed expression and overexpression.</title><p>A.<italic toggle="yes">SRD5A3</italic> expression in B cell lymphoma cells. B. Fluorescence after <italic toggle="yes">SRD5A3</italic> suppressed expression. C. <italic toggle="yes">SRD5A3</italic> cDNA levels after <italic toggle="yes">SRD5A3</italic> suppressed expression. D. <italic toggle="yes">SRD5A3</italic> protein levels after <italic toggle="yes">SRD5A3</italic> suppressed expression. E. Fluorescence after <italic toggle="yes">SRD5A3</italic> overexpression. F. <italic toggle="yes">SRD5A3</italic> cDNA levels after <italic toggle="yes">SRD5A3</italic> overexpression. G. <italic toggle="yes">SRD5A3</italic> protein levels after <italic toggle="yes">SRD5A3</italic> overexpression. The significance is marked as p&#x02009;&#x0003c;&#x02009;0.05 *; p&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g008" position="float"/></fig></sec><sec id="sec021"><title>3.6 Upregulation of SRD5A3 promotes proliferation of B-cell non-Hodgkin lymphoma cells</title><p>To investigate whether <italic toggle="yes">SRD5A3</italic> affects the proliferation of B-NHL cells, the CCK-8 assay was used to detect the proliferation of cells in the oe-<italic toggle="yes">SRD5A3</italic> and oe-NC groups and the sh-<italic toggle="yes">SRD5A3</italic> and sh-NC groups. Cell growth curves were plotted based on the OD results. We found that knockdown of <italic toggle="yes">SRD5A3</italic> (sh-<italic toggle="yes">SRD5A3</italic>) resulted in significantly lower proliferative activity than that of control cells (sh-NC) (<xref rid="pone.0323965.g009" ref-type="fig">Fig 9A</xref>). In contrast, the proliferative activity of overexpressing <italic toggle="yes">SRD5A3</italic> (oe-<italic toggle="yes">SRD5A3</italic>) was significantly higher than that of control cells (oe-NC) (<xref rid="pone.0323965.g009" ref-type="fig">Fig 9B</xref>). These data suggest that the upregulation of <italic toggle="yes">SRD5A3</italic> promotes proliferation in B-NHL cell, conversely, the downregulation of <italic toggle="yes">SRD5A3</italic> inhibits proliferation in B-NHL cells.</p><fig position="float" id="pone.0323965.g009"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g009</object-id><label>Fig 9</label><caption><title>Effect of <italic toggle="yes">SRD5A3</italic> on the proliferation in B-cell non-Hodgkin lymphoma.</title><p>A. Inhibition of <italic toggle="yes">SRD5A3</italic> expression suppresses proliferation. B. Overexpression of <italic toggle="yes">SRD5A3</italic> promotes proliferation. The significance is marked as p&#x02009;&#x0003c;&#x02009;0.05 *; p&#x02009;&#x0003c;&#x02009;0.01 **; p&#x02009;&#x0003c;&#x02009;0.001 ***; p&#x02009;&#x0003c;&#x02009;0.0001 ****; p&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g009" position="float"/></fig></sec><sec id="sec022"><title>3.7 Upregulation of SRD5A3 inhibits apoptosis of B-cell non-Hodgkin lymphoma cells</title><p>To investigate whether <italic toggle="yes">SRD5A3</italic> affects cell proliferation by regulating apoptosis, we performed flow cytometry analysis of cells in the sh-<italic toggle="yes">SRD5A3</italic> and sh-NC and oe-<italic toggle="yes">SRD5A3</italic> and oe-NC groups. The results showed that the apoptosis rate was 33.05&#x02009;&#x000b1;&#x02009;0.93% in the sh-<italic toggle="yes">SRD5A3</italic> group and 10.69&#x02009;&#x000b1;&#x02009;2% in the sh-NC group, and the apoptosis level in the sh-<italic toggle="yes">SRD5A3</italic> group was significantly higher than that in the sh-NC group (<xref rid="pone.0323965.g010" ref-type="fig">Fig 10A</xref>); the apoptosis rate in the oe-<italic toggle="yes">SRD5A3</italic> group was 5.5&#x02009;&#x000b1;&#x02009;0.09%, and the oe-NC group cell apoptosis rate was 10.25&#x02009;&#x000b1;&#x02009;0.59%, and the apoptosis level in the oe-NC group was significantly higher than that in the oe-<italic toggle="yes">SRD5A3</italic> group (<xref rid="pone.0323965.g010" ref-type="fig">Fig 10B</xref>). These data indicate that the upregulation of <italic toggle="yes">SRD5A3</italic> attenuated apoptosis in B-NHL cell, conversely, the downregulation of <italic toggle="yes">SRD5A3</italic> promotes apoptosis in B-NHL cells.</p><fig position="float" id="pone.0323965.g010"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g010</object-id><label>Fig 10</label><caption><title>Effect of <italic toggle="yes">SRD5A3</italic> on apoptosis in B-cell non-Hodgkin lymphoma.</title><p>A. Inhibition of SRD5A3 expression promotes apoptosis. B. Overexpression of <italic toggle="yes">SRD5A3</italic> suppresses apoptosis. The significance is marked as p&#x02009;&#x0003c;&#x02009;0.05 *; p&#x02009;&#x0003c;&#x02009;0.01 **; p&#x02009;&#x0003c;&#x02009;0.001 ***; p&#x02009;&#x0003c;&#x02009;0.0001 ****; p&#x02009;&#x0003c;&#x02009;0.05 indicates statistical significance.</p></caption><graphic xlink:href="pone.0323965.g010" position="float"/></fig></sec><sec id="sec023"><title>3.8 Mechanism of SRD5A3 regulation of cell proliferation and apoptosis</title><p>To investigate the molecular mechanism by which <italic toggle="yes">SRD5A3</italic> regulates cell growth, we used protein blotting to detect the expression of PCNA proliferative protein, Bcl-2 anti-apoptotic protein, N-cadherin and Vimentin adhesion protein. We found that <italic toggle="yes">SRD5A3</italic> overexpression increased the expression of PCNA, BCL-2, N-cadherin, and Vimentin. Conversely, <italic toggle="yes">SRD5A3</italic> knockdown decreased their expression (<xref rid="pone.0323965.g011" ref-type="fig">Fig 11</xref>). It can be seen that up-regulation of <italic toggle="yes">SRD5A3</italic> increased the expression of PCNA, BCL-2, N-cadherin and Vimentin, resulting in enhanced cell proliferation and migration and attenuated apoptosis. Moreover, we verified the changes in PI3K-AKT signaling by Western blot experiments, which showed that SRD5A3 overexpression increased the levels of p-PI3K and p-AKT signaling proteins, and vice versa, SRD5A3 low expression inhibited the levels of p-PI3K and p-AKT signaling proteins (<xref rid="pone.0323965.g012" ref-type="fig">Fig 12</xref>). To further confirm that <italic toggle="yes">SRD5A3</italic> affects B-NHL development by regulating the PI3K-AKT signaling pathway, we treated <italic toggle="yes">SRD5A3</italic> knockdown and control cells with the PI3K inhibitor 3-MA drug, followed by Western blot experiments. The results showed that in Raji cells, p-PI3K and p-AKT protein levels were highest in the sh-NC group, intermediate in the sh-NC&#x02009;+&#x02009;3-MA and sh-<italic toggle="yes">SRD5A3</italic> groups, and lowest in the sh-<italic toggle="yes">SRD5A3</italic>+3-MA group (<xref rid="pone.0323965.g013" ref-type="fig">Fig 13A</xref>). These data suggest that <italic toggle="yes">SRD5A3</italic> knockdown reduces p-PI3K and p-AKT protein levels and that 3-MA drugs further enhance this reduction. Similarly, we treated <italic toggle="yes">SRD5A3</italic> overexpression group and control cells with 3-MA drugs and performed Western blot experiments. The results showed that in SU-DHL-4 cells, the cells in the oe-<italic toggle="yes">SRD5A3</italic> group had the highest levels of p-PI3K and p-AKT proteins, the oe-NC group and the oe-SRD5A3+3-MA group had intermediate levels of p-PI3K and p-AKT proteins, and the oe-NC&#x02009;+&#x02009;3-MA group had the lowest levels of the proteins (<xref rid="pone.0323965.g013" ref-type="fig">Fig 13B</xref>). These data suggest that <italic toggle="yes">SRD5A3</italic> overexpression enhances p-PI3K and p-AKT protein levels, and that 3-MA reverses the enhancing effect of <italic toggle="yes">SRD5A3</italic> overexpression on p-PI3K and p-AKT protein levels. These experimental data further confirmed that <italic toggle="yes">SRD5A3</italic> acts through regulating the PI3K-AKT signaling pathway.</p><fig position="float" id="pone.0323965.g011"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g011</object-id><label>Fig 11</label><caption><title>Mechanism of <italic toggle="yes">SRD5A3</italic> regulates B-NHL cell proliferation and apoptosis.</title></caption><graphic xlink:href="pone.0323965.g011" position="float"/></fig><fig position="float" id="pone.0323965.g012"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g012</object-id><label>Fig 12</label><caption><title>Signaling pathways associated with the function of <italic toggle="yes">SRD5A3.</italic></title></caption><graphic xlink:href="pone.0323965.g012" position="float"/></fig><fig position="float" id="pone.0323965.g013"><object-id pub-id-type="doi">10.1371/journal.pone.0323965.g013</object-id><label>Fig 13</label><caption><title>Effects of PI3K pathway inhibitors on PI3K-AKT signaling proteins in SRD5A3 knockdown and overexpression cells.</title></caption><graphic xlink:href="pone.0323965.g013" position="float"/></fig></sec></sec><sec sec-type="conclusions" id="sec024"><title>4. Discussion</title><p><italic toggle="yes">SRD5A3</italic> is a member of the SRD5A family and is a protein-coding gene, which are located on chromosome 4 of the human genome and is approximately 36&#x02009;kDa in length. It is an important molecule for glycosylation metabolism and steroid hormone formation [<xref rid="pone.0323965.ref016" ref-type="bibr">16</xref>]. Steroid hormones are essential for the mammalian stress response, immunomodulation, and reproduction. Steroids, testosterone, and progesterone are catalytically produced by steroid 5&#x003b1;-reductase (SRD5As) and are important in a variety of physiological and pathological processes [<xref rid="pone.0323965.ref023" ref-type="bibr">23</xref>]. Glycosylation is a very important form of post-translational modification of proteins, which directly interacts with the surrounding environment or indirectly alters the conformation and stability of the protein [<xref rid="pone.0323965.ref017" ref-type="bibr">17</xref>]. Glycosylated proteins are involved in a variety of biological processes, and aberrant glycosylation is closely associated with many pathological processes such as tumorigenesis and inflammatory responses [<xref rid="pone.0323965.ref018" ref-type="bibr">18</xref>]. Glycosylation modifications affect tumor cell migration and invasion not only through the connection between the extracellular matrix and transmembrane proteins but also by modulating metastasis-related molecular signaling pathways. For example, E-cadherin, integrins, and mucins can alter the structure and function of glycoproteins, leading to abnormal glycosylation and promotion of tumor metastasis [<xref rid="pone.0323965.ref024" ref-type="bibr">24</xref>]. Pu C et al. showed that abnormal glycosylation promotes the development of endometrial and breast cancer [<xref rid="pone.0323965.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0323965.ref025" ref-type="bibr">25</xref>].</p><p>Non-Hodgkin&#x02019;s lymphoma (NHL) is the most common hematologic malignancy arising from lymphoid tissue, with approximately 85% originating from B lymphocytes [<xref rid="pone.0323965.ref026" ref-type="bibr">26</xref>]. B-NHL is characterized by heterogeneity in clinical presentation and course, ranging from asymptomatic and inert to highly aggressive [<xref rid="pone.0323965.ref027" ref-type="bibr">27</xref>]. Chemoimmunotherapy remains the first-line standard of care for aggressive B-NHL. However, a study by Frontzek F et al. found that high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation did not improve outcomes in high-risk aggressive B-cell lymphomas patients, but instead showed significant toxicity [<xref rid="pone.0323965.ref028" ref-type="bibr">28</xref>]. Therefore, the search for new targets to improve treatment and outcomes in B-NHL patients remains urgent. Further research on B-NHL-related genes will help to improve our understanding of the pathogenesis of the disease, thereby improving the treatment and survival of these patients. Our study found that <italic toggle="yes">SRD5A3</italic> was highly expressed in most tumors, such as B-NHL, breast, liver, colorectal, and ovarian cancer, compared to normal control tissues, and that patients with <italic toggle="yes">SRD5A3</italic> high expression had a poor OS. Studies have shown that <italic toggle="yes">SRD5A3</italic> expression is usually higher in a variety of tumor tissues than in non-tumor tissues. For example, <italic toggle="yes">SRD5A3</italic> is overexpressed in hepatocellular carcinoma, breast carcinoma, endometrial carcinoma, and prostate carcinoma, and patients with <italic toggle="yes">SRD5A3</italic> high expression suggest a poor prognosis [<xref rid="pone.0323965.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0323965.ref021" ref-type="bibr">21</xref>]. We also explored the relationship between <italic toggle="yes">SRD5A3</italic> and the clinicopathological features and prognosis of the B-NHL dataset GSE10846 and established a prognostic prediction model that included <italic toggle="yes">SRD5A3</italic>. We found that <italic toggle="yes">SRD5A3</italic> expression was higher in patients with&#x02265; 60 years old, high levels of LDH, stage III-IV, non-GCB subtype and extranodal invasion, while there were no significant differences in ECOG score subgroups. Survival analysis revealed longer OS in patients with low expression of <italic toggle="yes">SRD5A3</italic>,&#x02009;&#x0003c;&#x02009;60 years old, low LDH levels, low ECOG scores, low clinical stage, GCB subtype and without extranodal invasion, whereas sex had no significant effect on prognosis. That is in agreement with the findings of Bardakci M [<xref rid="pone.0323965.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0323965.ref033" ref-type="bibr">33</xref>] et al. Subsequently, we performed a multivariate COX regression analysis, which showed that <italic toggle="yes">SRD5A3</italic>, subtype and extranodal invasion were independent prognostic factors for OS in B-NHL patients. The C-index of nomogram was 0.725, indicating that the prognostic model had moderate predictive power. The results of the ROC curves showed that the prognostic model had a moderate ability to predict 1-,3- and 5-years survival in B-NHL patients.</p><p>We speculate that <italic toggle="yes">SRD5A3</italic> plays an important role in the pathogenesis of B-NHL and provide preliminary evidence supporting <italic toggle="yes">SRD5A3</italic> as a potential therapeutic target and prognostic marker. In SU-DHL-4 cells, <italic toggle="yes">SRD5A3</italic> overexpression promoted proliferation and attenuated apoptosis, whereas in Raji cells, <italic toggle="yes">SRD5A3</italic> knockdown inhibited proliferation and enhanced apoptosis. This suggests that <italic toggle="yes">SRD5A3</italic> is pro-carcinogenic and involved in the proliferation of cancer cells, which is consistent with previous findings in other tumors [<xref rid="pone.0323965.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0323965.ref022" ref-type="bibr">22</xref>]. A study by Mai Q et al. used hepatocellular carcinoma cells with knocked down <italic toggle="yes">SRD5A3</italic> to de-inoculate the subcutaneous tissue of nude mice, and found that downregulation of <italic toggle="yes">SRD5A3</italic> inhibited hepatocellular carcinoma growth [<xref rid="pone.0323965.ref016" ref-type="bibr">16</xref>]. In our study, we found that upregulation of <italic toggle="yes">SRD5A3</italic> increased BCL-2 anti-apoptotic proteins, PCNA proliferative proteins, and N-cadherin and Vimentin proteins, conversely, downregulation of <italic toggle="yes">SRD5A3</italic> suppressed these protein levels.</p><p>We performed GSEA pathway enrichment analysis on the differentially expressed genes and found that they were mainly enriched in signaling pathways such as JAK-STAT, PI3K-AKT, apoptosis, and transcription factor dysregulation in cancer. Studies have reported mutations that activate JAK or other upstream oncogenes, which, in turn, activate STAT, leading to tumorigenesis [<xref rid="pone.0323965.ref034" ref-type="bibr">34</xref>]. Song et al. found that STAT3 is constitutively activated in tumors such as DLBCL, head and neck cancer, and colorectal cancer [<xref rid="pone.0323965.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0323965.ref037" ref-type="bibr">37</xref>]. Many studies have reported that the PI3K-AKT-mTOR pathway is active in various tumors, and related drugs such as PI3K, AKT, and mTOR inhibitors have been used in the clinical treatment of DLBCL [<xref rid="pone.0323965.ref038" ref-type="bibr">38</xref>&#x02013;<xref rid="pone.0323965.ref040" ref-type="bibr">40</xref>]. In this study, we verified how <italic toggle="yes">SRD5A3</italic> regulates PI3K-ATK signaling by Western blot assay, The results showed that downregulation of <italic toggle="yes">SRD5A3</italic> inhibited p-PI3K and p-AKT protein levels, and PI3K inhibitors further enhanced the inhibitory effect of <italic toggle="yes">SRD5A3</italic> knockdown on p-PI3K and p-AKT protein levels. In contrast, upregulation of <italic toggle="yes">SRD5A3</italic> enhanced p-PI3K and p-AKT protein levels, and PI3K inhibitors reversed the enhancement of p-PI3K and p-AKT protein levels by <italic toggle="yes">SRD5A3</italic> overexpression. These results further confirm that <italic toggle="yes">SRD5A3</italic> acts by regulating the PI3K-AKT signaling pathway.</p></sec><sec sec-type="conclusions" id="sec025"><title>5. Conclusion</title><p>In summary, we found that <italic toggle="yes">SRD5A3</italic> is highly expressed in most tumors, including B-NHL, and may play a role in the development of B-NHL, suggesting poor prognosis. <italic toggle="yes">SRD5A3</italic> promotes B-NHL cell proliferation and attenuates cancer cell apoptosis by regulating the PI3K-AKT signaling pathway. Our data suggest that <italic toggle="yes">SRD5A3</italic> functions as an oncogene, which may serve as a potential prognostic biomarker and therapeutic target for B-NHL.</p><p>However, the shortcoming of this study is that we did not further validate the effect of <italic toggle="yes">SRD5A3</italic> expression level on the growth of B-NHL by in vivo nude mice subcutaneous tumor formation experiments, which will be explored in the next step.</p></sec><sec id="sec026" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0323965.s001" position="float" content-type="local-data"><label>S1 File</label><caption><title>The original uncropped and unadjusted Western blot images.</title><p>(XLSX)</p></caption><media xlink:href="pone.0323965.s001.xlsx"/></supplementary-material><supplementary-material id="pone.0323965.s002" position="float" content-type="local-data"><label>S2 File</label><caption><title>The original plotting data.</title><p>(PDF)</p></caption><media xlink:href="pone.0323965.s002.pdf"/></supplementary-material></sec></body><back><ack><p>Not applicable.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>
<italic toggle="yes">SRD5A3</italic>
</term><def><p>Steroid 5 alpha-reductase 3</p></def></def-item><def-item><term>B-NHL</term><def><p>B-cell non-Hodgkin lymphoma</p></def></def-item><def-item><term>LDH</term><def><p>lactate dehydrogenase</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>DLBCL</term><def><p>diffuse large B-cell lymphoma</p></def></def-item><def-item><term>BL</term><def><p>Burkitt&#x02019;s lymphoma</p></def></def-item><def-item><term>MCL</term><def><p>Mantle-cell lymphoma</p></def></def-item><def-item><term>ASCT</term><def><p>autologous stem cell transplantation</p></def></def-item><def-item><term>CAR-T</term><def><p>chimeric antigen receptor T cell</p></def></def-item><def-item><term>IPI</term><def><p>International Prognostic Index</p></def></def-item><def-item><term>aaIPI</term><def><p>age adjusted International Prognostic Index</p></def></def-item><def-item><term>NCCN-IPI</term><def><p>NCCN International Prognostic Index</p></def></def-item><def-item><term>EZH2</term><def><p>enhancer of zeste homolog</p></def></def-item><def-item><term>MYD88</term><def><p>myeloid differentiation factor 88</p></def></def-item><def-item><term>CD79B</term><def><p>B-cell antigen receptor complex-associated protein beta chain</p></def></def-item><def-item><term>BCL-2</term><def><p>B-cell lymphoma-2</p></def></def-item><def-item><term>TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item><def-item><term>GTEx</term><def><p>Genotype-Tissue Expression</p></def></def-item><def-item><term>GEO</term><def><p>Gene Expression Omnibus</p></def></def-item><def-item><term>ECOG</term><def><p>Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>GSEA</term><def><p>Gene Set Enrichment Analysis</p></def></def-item><def-item><term>RT-qPCR</term><def><p>Quantitative Real-time PCR.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0323965.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Chapuy</surname><given-names>B</given-names></name>, <name><surname>Stewart</surname><given-names>C</given-names></name>, <name><surname>Dunford</surname><given-names>AJ</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Kamburov</surname><given-names>A</given-names></name>, <name><surname>Redd</surname><given-names>RA</given-names></name>, <etal>et al</etal>. <article-title>Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes</article-title>. <source>Nat Med</source>. <year>2018</year>;<volume>24</volume>(<issue>5</issue>):<fpage>679</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41591-018-0016-8</pub-id>
<pub-id pub-id-type="pmid">29713087</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Ennishi</surname><given-names>D</given-names></name>, <name><surname>Hsi</surname><given-names>ED</given-names></name>, <name><surname>Steidl</surname><given-names>C</given-names></name>, <name><surname>Scott</surname><given-names>DW</given-names></name>. <article-title>Toward a new molecular taxonomy of diffuse large B-cell lymphoma</article-title>. <source>Cancer Discov</source>. <year>2020</year>;<volume>10</volume>(<issue>9</issue>):<fpage>1267</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0174</pub-id>
<pub-id pub-id-type="pmid">32616477</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Iqbal</surname><given-names>J</given-names></name>, <name><surname>Naushad</surname><given-names>H</given-names></name>, <name><surname>Bi</surname><given-names>C</given-names></name>, <name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Bouska</surname><given-names>A</given-names></name>, <name><surname>Rohr</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?</article-title>. <source>Blood Rev</source>. <year>2016</year>;<volume>30</volume>(<issue>2</issue>):<fpage>73</fpage>&#x02013;<lpage>88</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.blre.2015.08.002</pub-id>
<pub-id pub-id-type="pmid">26432520</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Lv</surname><given-names>Y</given-names></name>, <name><surname>Du</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>K</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Du</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin&#x02019;s lymphoma tumor growth by promoting apoptosis and autophagy</article-title>. <source>Cell Commun Signal</source>. <year>2023</year>;<volume>21</volume>(<issue>1</issue>):<fpage>16</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12964-022-01031-x</pub-id>
<pub-id pub-id-type="pmid">36691066</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Sehn</surname><given-names>LH</given-names></name>, <name><surname>Salles</surname><given-names>G</given-names></name>. <article-title>Diffuse Large B-Cell Lymphoma</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>9</issue>):<fpage>842</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">33657296</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Raut</surname><given-names>LS</given-names></name>, <name><surname>Chakrabarti</surname><given-names>PP</given-names></name>. <article-title>Management of relapsed-refractory diffuse large B cell lymphoma</article-title>. <source>South Asian J Cancer</source>. <year>2014</year>;<volume>3</volume>(<issue>1</issue>):<fpage>66</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/2278-330X.126531</pub-id>
<pub-id pub-id-type="pmid">24665451</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref007"><label>7</label><mixed-citation publication-type="book"><name><surname>Wild</surname><given-names>CP</given-names></name>, <name><surname>Weiderpass</surname><given-names>E</given-names></name>, <name><surname>Stewart</surname><given-names>BW</given-names></name>. <source>Cancer Research for Cancer Prevention[R]</source>. <publisher-name>World Cancer Reports</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="pone.0323965.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Barta</surname><given-names>SK</given-names></name>. <article-title>Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment</article-title>. <source>Am J Hematol</source>. <year>2019</year>;<volume>94</volume>(<issue>5</issue>):<fpage>604</fpage>&#x02013;<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ajh.25460</pub-id>
<pub-id pub-id-type="pmid">30859597</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Maurer</surname><given-names>MJ</given-names></name>. <article-title>The International Prognostic Index in aggressive B-cell lymphoma</article-title>. <source>Haematologica</source>. <year>2023</year>;<volume>108</volume>(<issue>11</issue>):<fpage>2874</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3324/haematol.2023.284070</pub-id>
<pub-id pub-id-type="pmid">37916449</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Alizadeh</surname><given-names>AA</given-names></name>, <name><surname>Eisen</surname><given-names>MB</given-names></name>, <name><surname>Davis</surname><given-names>RE</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Lossos</surname><given-names>IS</given-names></name>, <name><surname>Rosenwald</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</article-title>. <source>Nature</source>. <year>2000</year>;<volume>403</volume>(<issue>6769</issue>):<fpage>503</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/35000501</pub-id>
<pub-id pub-id-type="pmid">10676951</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Souroullas</surname><given-names>GP</given-names></name>, <name><surname>Jeck</surname><given-names>WR</given-names></name>, <name><surname>Parker</surname><given-names>JS</given-names></name>, <name><surname>Simon</surname><given-names>JM</given-names></name>, <name><surname>Liu</surname><given-names>J-Y</given-names></name>, <name><surname>Paulk</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>(<issue>6</issue>):<fpage>632</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nm.4092</pub-id>
<pub-id pub-id-type="pmid">27135738</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Berg</surname><given-names>T</given-names></name>, <name><surname>Thoene</surname><given-names>S</given-names></name>, <name><surname>Yap</surname><given-names>D</given-names></name>, <name><surname>Wee</surname><given-names>T</given-names></name>, <name><surname>Schoeler</surname><given-names>N</given-names></name>, <name><surname>Rosten</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis</article-title>. <source>Blood</source>. <year>2014</year>;<volume>123</volume>(<issue>25</issue>):<fpage>3914</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2012-12-473439</pub-id>
<pub-id pub-id-type="pmid">24802772</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Knittel</surname><given-names>G</given-names></name>, <name><surname>Liedgens</surname><given-names>P</given-names></name>, <name><surname>Korovkina</surname><given-names>D</given-names></name>, <name><surname>Seeger</surname><given-names>JM</given-names></name>, <name><surname>Al-Baldawi</surname><given-names>Y</given-names></name>, <name><surname>Al-Maarri</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice</article-title>. <source>Blood</source>. <year>2016</year>;<volume>127</volume>(<issue>22</issue>):<fpage>2732</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2015-11-684183</pub-id>
<pub-id pub-id-type="pmid">27048211</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Janz</surname><given-names>S</given-names></name>. <article-title>Mouse model of MYD88L265P-dependent DLBCL</article-title>. <source>Blood</source>. <year>2016</year>;<volume>127</volume>(<issue>22</issue>):<fpage>2660</fpage>&#x02013;<lpage>1</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2016-04-710434</pub-id>
<pub-id pub-id-type="pmid">27257177</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Dubois</surname><given-names>S</given-names></name>, <name><surname>Jardin</surname><given-names>F</given-names></name>. <article-title>Novel molecular classifications of DLBCL</article-title>. <source>Nat Rev Clin Oncol</source>. <year>2018</year>;<volume>15</volume>(<issue>8</issue>):<fpage>474</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41571-018-0041-z</pub-id>
<pub-id pub-id-type="pmid">29789700</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Mai</surname><given-names>Q</given-names></name>, <name><surname>Sheng</surname><given-names>D</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Gou</surname><given-names>Q</given-names></name>, <name><surname>Chen</surname><given-names>M</given-names></name>, <name><surname>Huang</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC)</article-title>. <source>Aging (Albany NY)</source>. <year>2020</year>;<volume>12</volume>(<issue>24</issue>):<fpage>25395</fpage>&#x02013;<lpage>411</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/aging.104142</pub-id>
<pub-id pub-id-type="pmid">33229626</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>de Vries</surname><given-names>T</given-names></name>, <name><surname>Knegtel</surname><given-names>RM</given-names></name>, <name><surname>Holmes</surname><given-names>EH</given-names></name>, <name><surname>Macher</surname><given-names>BA</given-names></name>. <article-title>Fucosyltransferases: structure/function studies</article-title>. <source>Glycobiology</source>. <year>2001</year>;<volume>11</volume>(<issue>10</issue>):119R-128R. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/glycob/11.10.119r</pub-id>
<pub-id pub-id-type="pmid">11588153</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>LADENSON</surname><given-names>RP</given-names></name>, <name><surname>SCHWARTZ</surname><given-names>SO</given-names></name>, <name><surname>IVY</surname><given-names>AC</given-names></name>. <article-title>Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma</article-title>. <source>Am J Med Sci</source>. <year>1949</year>;<volume>217</volume>(<issue>2</issue>):<fpage>194</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/00000441-194902000-00011</pub-id>
<pub-id pub-id-type="pmid">18109280</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Ch&#x000e1;vez</surname><given-names>B</given-names></name>, <name><surname>Ramos</surname><given-names>L</given-names></name>, <name><surname>Garc&#x000ed;a-Becerra</surname><given-names>R</given-names></name>, <name><surname>Vilchis</surname><given-names>F</given-names></name>. <article-title>Hamster SRD5A3 lacks steroid 5&#x003b1;-reductase activity in vitro</article-title>. <source>Steroids</source>. <year>2015</year>;<volume>94</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.steroids.2014.11.005</pub-id>
<pub-id pub-id-type="pmid">25498908</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z-H</given-names></name>, <name><surname>Zhang</surname><given-names>Y-Z</given-names></name>, <name><surname>Wang</surname><given-names>Y-S</given-names></name>, <name><surname>Ma</surname><given-names>X-X</given-names></name>. <article-title>Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer</article-title>. <source>Cancer Cell Int</source>. <year>2019</year>;<volume>19</volume>:<fpage>296</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12935-019-1001-0</pub-id>
<pub-id pub-id-type="pmid">31807118</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Shaughnessy</surname><given-names>P</given-names></name>, <name><surname>Monteiro</surname><given-names>A</given-names></name>, <name><surname>Bhattacharya</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy</article-title>. <source>Mol Hum Reprod</source>. <year>2013</year>;<volume>19</volume>(<issue>3</issue>):<fpage>177</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">23197595</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y-P</given-names></name>, <name><surname>Na</surname><given-names>W-T</given-names></name>, <name><surname>Dai</surname><given-names>X-Q</given-names></name>, <name><surname>Li</surname><given-names>R-F</given-names></name>, <name><surname>Wang</surname><given-names>J-X</given-names></name>, <name><surname>Gao</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Over-expression of SRD5A3 and its prognostic significance in breast cancer</article-title>. <source>World J Surg Oncol</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>260</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12957-021-02377-1</pub-id>
<pub-id pub-id-type="pmid">34465365</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Zhuang</surname><given-names>Q</given-names></name>, <name><surname>Sun</surname><given-names>B</given-names></name>, <name><surname>Lv</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Xiao</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>449</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-020-20675-2</pub-id>
<pub-id pub-id-type="pmid">33469028</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>DA</given-names></name>, <name><surname>Drake</surname><given-names>RR</given-names></name>. <article-title>Glycosylation and its implications in breast cancer</article-title>. <source>Expert Rev Proteomics</source>. <year>2019</year>;<volume>16</volume>(<issue>8</issue>):<fpage>665</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/14789450.2019.1645604</pub-id>
<pub-id pub-id-type="pmid">31314995</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Pu</surname><given-names>C</given-names></name>, , <name><surname>Xu</surname><given-names>K</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>. <article-title>Glycosylation and its research progress in endometrial cancer</article-title>. <source>Clin Transl Oncol</source>. <year>2022</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1865</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">35752750</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>F</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Ke</surname><given-names>X</given-names></name>. <article-title>Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma</article-title>. <source>Int J Oncol</source>. <year>2016</year>;<volume>48</volume>(<issue>4</issue>):<fpage>1561</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">26891663</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Silkenstedt</surname><given-names>E</given-names></name>, <name><surname>Salles</surname><given-names>G</given-names></name>, <name><surname>Campo</surname><given-names>E</given-names></name>, <name><surname>Dreyling</surname><given-names>M</given-names></name>. <article-title>B-cell non-Hodgkin lymphomas</article-title>. <source>Lancet</source>. <year>2024</year>;<volume>403</volume>(<issue>10438</issue>):<fpage>1791</fpage>&#x02013;<lpage>807</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02705-8</pub-id>
<pub-id pub-id-type="pmid">38614113</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Frontzek</surname><given-names>F</given-names></name>, <name><surname>Ziepert</surname><given-names>M</given-names></name>, <name><surname>Nickelsen</surname><given-names>M</given-names></name>, <name><surname>Altmann</surname><given-names>B</given-names></name>, <name><surname>Glass</surname><given-names>B</given-names></name>, <name><surname>Haenel</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial</article-title>. <source>Lancet Haematol</source>. <year>2021</year>;<volume>8</volume>(<issue>4</issue>):e267&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2352-3026(21)00022-3</pub-id>
<pub-id pub-id-type="pmid">33667420</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Varelas</surname><given-names>AN</given-names></name>, <name><surname>Eggerstedt</surname><given-names>M</given-names></name>, <name><surname>Ganti</surname><given-names>A</given-names></name>, <name><surname>Tajudeen</surname><given-names>BA</given-names></name>. <article-title>Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B -cell lymphoma</article-title>. <source>Laryngoscope</source>. <year>2019</year>;<volume>129</volume>(<issue>6</issue>):<fpage>1259</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/lary.27639</pub-id>
<pub-id pub-id-type="pmid">30570148</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Bardakci</surname><given-names>M</given-names></name>, <name><surname>Esmer</surname><given-names>DD</given-names></name>, <name><surname>Hafizoglu</surname><given-names>E</given-names></name>, <name><surname>Karaman</surname><given-names>K</given-names></name>, <name><surname>Kuzu</surname><given-names>OF</given-names></name>, <name><surname>Karakas</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience</article-title>. <source>J Cancer Res Ther</source>. <year>2023</year>;<volume>19</volume>(<issue>3</issue>):<fpage>778</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/jcrt.jcrt_2111_21</pub-id>
<pub-id pub-id-type="pmid">37470610</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>Yuan</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Identification and validation of a prognostic prediction model in diffuse large B-cell lymphoma</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2022</year>;<volume>13</volume>:<fpage>846357</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fendo.2022.846357</pub-id>
<pub-id pub-id-type="pmid">35498426</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ad&#x00131;yaman</surname><given-names>SC</given-names></name>, <name><surname>Alacac&#x00131;o&#x0011f;lu</surname><given-names>&#x00130;</given-names></name>, <name><surname>Ersen Danyeli</surname><given-names>A</given-names></name>, <name><surname>T&#x000fc;rky&#x00131;lmaz</surname><given-names>D</given-names></name>, <name><surname>Sevindik</surname><given-names>&#x000d6;G</given-names></name>, <name><surname>Demirkan</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Prognostic factors in elderly patients with diffuse large B-Cell lymphoma and their treatment results</article-title>. <source>Turk J Haematol</source>. <year>2019</year>;<volume>36</volume>(<issue>2</issue>):<fpage>81</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4274/tjh.galenos.2019.2018.0219</pub-id>
<pub-id pub-id-type="pmid">30724061</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Zhou</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Prognostic nomogram for overall survival in patients with diffuse large B-Cell lymphoma</article-title>. <source>Oncologist</source>. <year>2019</year>;<volume>24</volume>(<issue>11</issue>):e1251&#x02013;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0361</pub-id>
<pub-id pub-id-type="pmid">30952824</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name>, <name><surname>Schwartz</surname><given-names>DM</given-names></name>, <name><surname>Villarino</surname><given-names>AV</given-names></name>, <name><surname>Gadina</surname><given-names>M</given-names></name>, <name><surname>McInnes</surname><given-names>IB</given-names></name>, <name><surname>Laurence</surname><given-names>A</given-names></name>. <article-title>The JAK-STAT pathway: impact on human disease and therapeutic intervention</article-title>. <source>Annu Rev Med</source>. <year>2015</year>;<volume>66</volume>:<fpage>311</fpage>&#x02013;<lpage>28</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev-med-051113-024537</pub-id>
<pub-id pub-id-type="pmid">25587654</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>JI</given-names></name>, <name><surname>Grandis</surname><given-names>JR</given-names></name>. <article-title>STAT signaling in head and neck cancer</article-title>. <source>Oncogene</source>. <year>2000</year>;<volume>19</volume>(<issue>21</issue>):<fpage>2489</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.onc.1203483</pub-id>
<pub-id pub-id-type="pmid">10851047</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Kryczek</surname><given-names>I</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Nagarsheth</surname><given-names>N</given-names></name>, <name><surname>Peng</surname><given-names>D</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L</article-title>. <source>Immunity</source>. <year>2014</year>;<volume>40</volume>(<issue>5</issue>):<fpage>772</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2014.03.010</pub-id>
<pub-id pub-id-type="pmid">24816405</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Lam</surname><given-names>LT</given-names></name>, <name><surname>Wright</surname><given-names>G</given-names></name>, <name><surname>Davis</surname><given-names>RE</given-names></name>, <name><surname>Lenz</surname><given-names>G</given-names></name>, <name><surname>Farinha</surname><given-names>P</given-names></name>, <name><surname>Dang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma</article-title>. <source>Blood</source>. <year>2008</year>;<volume>111</volume>(<issue>7</issue>):<fpage>3701</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood-2007-09-111948</pub-id>
<pub-id pub-id-type="pmid">18160665</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Majchrzak</surname><given-names>A</given-names></name>, <name><surname>Witkowska</surname><given-names>M</given-names></name>, <name><surname>Smolewski</surname><given-names>P</given-names></name>. <article-title>Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance</article-title>. <source>Molecules</source>. <year>2014</year>;<volume>19</volume>(<issue>9</issue>):<fpage>14304</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/molecules190914304</pub-id>
<pub-id pub-id-type="pmid">25215588</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Petrich</surname><given-names>A</given-names></name>, <name><surname>Leshchenko</surname><given-names>V</given-names></name>, <name><surname>Kuo</surname><given-names>P-Y</given-names></name>. <article-title>Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in DLBCL</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>;<volume>18</volume>:<fpage>2534</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22338016</pub-id>
</mixed-citation></ref><ref id="pone.0323965.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Qazi</surname><given-names>AK</given-names></name>, <name><surname>Hussain</surname><given-names>A</given-names></name>, <name><surname>Hamid</surname><given-names>A</given-names></name>, <name><surname>Qurishi</surname><given-names>Y</given-names></name>, <name><surname>Majeed</surname><given-names>R</given-names></name>, <name><surname>Ahmad</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies</article-title>. <source>Anticancer Agents Med Chem</source>. <year>2013</year>;<volume>13</volume>(<issue>10</issue>):<fpage>1552</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/1871520613666131125123241</pub-id>
<pub-id pub-id-type="pmid">23438828</pub-id>
</mixed-citation></ref></ref-list></back></article>